Department of Medicine, Stony Brook University School of Medicine, HSC-T17 Room 090, Stony Brook, NY 11794, USA.
Future Oncol. 2012 Mar;8(3):259-72. doi: 10.2217/fon.12.19.
Recent advancements in understanding the role of both genetics and molecular pathways in the formation and progression of colorectal cancer have allowed the identification of factors that may be targeted for drug discovery. During the past decade, various approaches have been developed to target specific steps or components of these pathways in order to prevent the development and progression of colorectal cancer and to treat this disease. The innovation and optimization of high-throughput screening methods, as well as the recent emphasis from the NIH on translational sciences, have enabled rapid progress in drug discovery in many fields, including colorectal cancer. Here we present a summary of the recent efforts of targeted high-throughput drug discovery directed at pathways affected in colorectal cancer.
近年来，人们对遗传和分子途径在结直肠癌形成和发展中的作用的认识不断深入，这使得人们能够识别出可能成为药物研发靶点的因素。在过去的十年中，已经开发出各种方法来针对这些途径的特定步骤或成分进行靶向治疗，以预防结直肠癌的发生和发展，并治疗这种疾病。高通量筛选方法的创新和优化，以及 NIH 最近对转化科学的重视，使得包括结直肠癌在内的许多领域的药物发现取得了快速进展。在这里，我们总结了针对结直肠癌相关途径的靶向高通量药物发现的最新努力。
